With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics. But will sidestepping normal regulatory protocols actually be a net negative for the field?
Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients Read More »
Unos científicos han descubierto un método sencillo para generar hidrógeno gaseoso mezclando metanol, hidróxido de sodio e iones de hierro, y luego irradiando la solución con luz ultravioleta. Además, la actividad catalítica de la reacción es c …
El río Colorado —que no siempre ha discurrido por la región del Gran Cañón— quizá comenzó a abrirse paso a través de su cauce actual tras el desbordamiento de un antiguo lago hace aproximadamente 5,6 millones de años, según s …
Un nuevo estudio revisa el papel del ácido palmítico y el ácido oleico —los principales ácidos grasos de la dieta— en el desarrollo de la diabetes mellitus de tipo 2, una enfermedad crónica que causa una elevada morbilidad y mortalidad en todo el mundo. …
Calidad frente a cantidad de la grasa en la dieta Read More »
The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.
Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision Read More »
Finding the right people for critical open roles can be difficult even for biopharma leaders. In this column, Kaye/Bassman’s Michael Pietrack discusses four pitfalls executives face during the hiring process, starting with confusing scientific brilliance with leadership ability.
The 4 biggest hiring mistakes biopharma executives keep making Read More »
Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.
Lilly, Novo dip as proposed Medicare coverage for GLP-1 pilot thrown off balance Read More »
The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking over cell therapy-focused Neurona Therapeutics; President Trump signed a new executive order supporting the development of psychedelic therapies, sparking fanfare and concern alike; and the FDA’s recent Replimune decision has triggered broader debate about
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous system indications.
Lilly exits Rigel alliance, adding to RIPK1 scrap heap Read More »
In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for resubmission remains uncertain.
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot Read More »
